###begin article-title 0
###xml 15 19 15 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 304 308 304 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 310 315 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 319 324 319 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
Lynch syndrome (LS) is associated with a high risk for colorectal cancer (CRC) and extracolonic malignancies, such as endometrial carcinoma (EC). The risk is dependent of the affected mismatch repair gene. The aim of the present study was to calculate the cumulative risk of LS related cancers in proven MLH1, MSH2 and MSH6 mutation carriers.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
The studypopulation consisted out of 67 proven LS families. Clinical information including mutation status and tumour diagnosis was collected. Cumulative risks were calculated and compared using Kaplan Meier survival analysis.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 230 235 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 308 313 308 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 323 328 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 406 411 406 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 415 419 415 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
MSH6 mutation carriers, both males and females had the lowest risk for developing CRC at age 70 years, 54% and 30% respectively and the age of onset was delayed by 3-5 years in males. With respect to endometrial carcinoma, female MSH6 mutation carriers had the highest risk at age 70 years (61%) compared to MLH1 (25%) and MSH2 (49%). Also, the age of EC onset was delayed by 5-10 years in comparison with MLH1 and MSH2.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 71 75 71 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 160 165 160 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 434 439 434 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 469 474 469 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 478 483 478 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
Although the cumulative lifetime risk of LS related cancer is similar, MLH1, MSH2 and MSH6 mutations seem to cause distinguishable cancer risk profiles. Female MSH6 mutation carriers have a lower CRC risk and a higher risk for developing endometrial carcinoma. As a consequence, surveillance colonoscopy starting at age 30 years instead of 20-25 years is more suitable. Also, prophylactic hysterectomy may be more indicated in female MSH6 mutation carriers compared to MLH1 and MSH2 mutation carriers.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 267 271 267 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 276 280 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 281 282 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 285 289 285 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6</italic>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 297 301 297 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PMS2</italic>
###xml 302 303 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 592 593 592 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 594 595 594 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer, is the most common hereditary colorectal cancer (CRC) syndrome and accounts for 2-5% of all colorectal cancer cases [1]. Germline mutations in any of the four mismatch repair (MMR) genes, MLH1[2], MSH2[3], MSH6[4] and PMS2[5], are the underlying cause of LS. Subjects carrying a mutation in one of the MMR genes have a higher risk for developing colorectal cancer, but also for endometrial carcinoma and malignancies of the stomach, small bowel, ovaries, upper uroepithelial tract, biliary tract, skin and brain [6-9].
###end p 10
###begin p 11
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 338 339 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 436 441 436 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 471 476 471 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 503 508 503 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 647 649 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 665 670 665 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PMS2 </italic>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
The colorectal cancer risk in LS is dependent on sex and the MMR gene involved. The reported lifetime risk for colorectal cancer in the literature varies from 28-100% in males and 25-83% in females [7,10-18]. The risk of developing endometrial carcinoma ranges from 30-71% and the risk of other LS-associated cancers is less than 10-15% [9]. Furthermore, some studies have suggested that extracolonic cancers are more often observed in MSH2 mutation families compared to MLH1 mutation families [13,19]. MSH6 mutation families probably have a milder clinical phenotype with a later onset of both CRC and EC and clustering of endometrial carcinoma [17]. The risks in PMS2 mutation families are largely unknown. One study reported that PMS2 mutation families have a milder phenotype compared to MLH1 and MSH2 families [20].
###end p 11
###begin p 12
###xml 413 418 413 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 422 427 422 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 463 468 463 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 811 815 811 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 817 822 817 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 826 831 826 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
Unfortunately, the precise lifetime risk for CRC and endometrial carcinoma may be biased because the families selected in previous studies were mainly selected on basis of clustering of CRC or fulfilment of clinical criteria (Amsterdam II criteria). Furthermore, it was not always clear whether the affected subjects were proven mutation carriers. In addition, most studies have only evaluated lifetime risks for MLH1 and MSH2 mutations, while studies evaluating MSH6 mutation families are sparse. The most efficient way to calculate the lifetime risks of CRC and EC in Lynch syndrome would be to calculate these risks based on a cohort of proven mutation carriers. Therefore, the aim of the present study was to calculate the cumulative lifetime risks for CRC and EC in Lynch syndrome using a cohort of proven MLH1, MSH2 and MSH6 mutation carriers.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Study population
###end title 14
###begin p 15
###xml 612 620 <span type="species:ncbi:9606">patients</span>
###xml 637 644 <span type="species:ncbi:9606">patient</span>
During the period 1994-2007, an MMR gene mutation was detected in 67 families who were counselled at the Department of Clinical Genetics of the Erasmus MC University Medical Center, because of a clinical suspicion for Lynch syndrome. Clinical data of family members including sex, age, mutation status, age at diagnosis of both LS-associated and other cancers were collected. LS-associated cancer included colorectal, endometrial, stomach, ovaries, upper uroepithelial tract, biliary tract, skin and brain cancer. Also, the site of the tumour, age at death and cause of death were collected. With consent of the patients or (in case the patient was deceased) of a close relative the cancer diagnosis was confirmed by pathology and/or medical reports. All pathology and medical reports were reviewed by the first author (DR) in order to confirm the diagnosis. If a subject reported the occurrence of cancer in the family and no pathology or medical report was available, the cancer was excluded from analysis. In addition, data regarding colonoscopic surveillance of affected and unaffected family members were collected.
###end p 15
###begin p 16
Only subjects with a proven MMR gene mutation were included in this study.
###end p 16
###begin title 17
Mutation analysis
###end title 17
###begin p 18
Mutation analysis was performed by denaturing gradient gel electrophoresis, sequencing and multiplex ligation-dependent probe amplification (MRC-Holland kits P003 and P008). Mutation nomenclature was used according to international guidelines . A variant was considered a mutation when leading to a predicted truncated protein or based on previously published data. Silent or missense variants which were previously unreported or of unclear status were labelled unclassified variants (UV) and not considered as an MMR gene mutation.
###end p 18
###begin title 19
Statistical analysis
###end title 19
###begin p 20
###xml 324 328 324 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 330 335 330 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 339 344 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
Data were submitted for statistical testing using the Statistical Package for the Social Sciences (SPSS Inc, Chicago, IL), version 12.0.1. Data are given as median and range or as mean with standard deviation when appropriate. The chi square test, Student's t test and log rank test were used to compare differences between MLH1, MSH2 and MSH6 mutation carriers. Penetrance for age was calculated using the Kaplan Meier survival analysis method and included the 67 index cases. In case of multiple or recurrent colorectal carcinoma or endometrial adenocarcinoma, only the first diagnosis of either cancer was included in the analysis. The observation time for the different cancers was from birth until the date of first cancer diagnosis, death, date of hysterectomy (only for the observation time of endometrial carcinoma) or the end of the study (31 December 2007). A p value below .05 was considered statistically significant.
###end p 20
###begin title 21
Results
###end title 21
###begin title 22
Study population
###end title 22
###begin p 23
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 109 114 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 144 149 144 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 364 365 364 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 1170 1175 1168 1173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 1324 1325 1322 1323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 272 275 <span type="species:ncbi:9606">men</span>
###xml 284 289 <span type="species:ncbi:9606">women</span>
###xml 341 344 <span type="species:ncbi:9606">men</span>
###xml 350 355 <span type="species:ncbi:9606">women</span>
In the 67 families with an MMR gene mutation, 26 (39%) were detected with an MLH1 mutation, 20 (30%) with an MSH2 mutation and 21 (31%) with an MSH6 mutation. Of the 67 families, 46 (69%) met the Amsterdam II criteria. Mutation analysis was performed in 725 subjects (296 men and 429 women) and a mutation was identified in 246 subjects (92 men, 154 women) (Table 1). At the time of mutation analysis the mean age of the 246 mutation carriers was 49 (+/- 16) years. Of the 246 mutation carriers, 115 (47%) were diagnosed with a Lynch syndrome associated tumour. One hundred and four (42%) mutation carriers already had been diagnosed with a Lynch syndrome associated tumour before mutation analysis was performed. Colorectal cancer was diagnosed in 83 (34%) mutation carriers, including 17 (7%) mutation carriers who developed 2 or more CRCs during their lifetime. Endometrial carcinoma was diagnosed in 37 (24%) of the 154 female mutation carriers, including 13 mutation carriers who also developed CRC during their life. Of the six families with a strong family history of endometrial carcinoma (two or more cases within the family), five (83%) were diagnosed with an MSH6 mutation. With respect to the other LS-associated cancers, 19 (8%) mutation carriers developed another LS-associated cancer during their life (Table 1). Seven of these nineteen mutation carriers were also diagnosed with CRC, one mutation carrier also with endometrial carcinoma and four mutation carriers with both CRC and EC. In total, 194 mutation carriers were under colonoscopic surveillance, including 69 subjects who had already been diagnosed with colorectal cancer before mutational testing was performed.
###end p 23
###begin p 24
Study population characteristics
###end p 24
###begin p 25
* No histological proven stomach cancers were reported.
###end p 25
###begin p 26
###xml 557 563 <span type="species:ncbi:9606">person</span>
One of the 69 mutation carriers had previously been diagnosed with EC and developed CRC while being under colonoscopic surveillance. The other 68 mutation carriers were included in a colonoscopic surveillance program after being diagnosed with colorectal cancer. These 68 subjects were treated surgically (partial colectomy) for colorectal cancer and colonoscopic surveillance of the remaining colon was performed. Of the remaining 125 mutation carriers none developed colorectal cancer and in 23 (18%) adenomatous polyps had been detected and removed. The person-years of follow up was 1414 years and the mean follow up time of the subjects under colonoscopic surveillance was 7 +/- 4 years.
###end p 26
###begin title 27
Lifetime risks
###end title 27
###begin p 28
###xml 57 58 57 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 67 68 67 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 77 78 77 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 90 91 90 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 211 215 211 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 225 230 225 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 242 247 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 481 485 481 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6</italic>
###xml 487 492 487 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 496 501 496 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 651 656 651 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 687 692 687 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 695 700 695 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 726 727 726 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
The respective lifetime risks curves are shown in figure 1, figure 2, figure 3 and figure 4. For all LS-associated tumours, the cumulative risks in both male and female mutation carriers at 70 years was 71% for MLH1, 77% for MSH2 and 75% for MSH6 mutation carriers (Figure 1). Although the cumulative risks at age 70 years were similar for the three different MMR genes, the log rank test showed a significant difference for developing any Lynch syndrome associated cancer between MSH6, MLH1 and MSH2 mutation carriers (p = 0.01). This was due to the fact that before the age of 70 years the risk of developing any Lynch syndrome associated cancer in MSH6 carriers was lower compared to MLH1 or MSH2 mutation carriers (Figure 1).
###end p 28
###begin p 29
###xml 0 139 0 139 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">All Lynch associated cancers (colorectal, endometrial, stomach, ovaries, upper uroepithelial tract, biliary tract, skin and brain cancer): </bold>
###xml 160 164 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 166 171 166 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 175 180 175 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
All Lynch associated cancers (colorectal, endometrial, stomach, ovaries, upper uroepithelial tract, biliary tract, skin and brain cancer): cumulative risks for MLH1, MSH2 and MSH6 mutation carriers.
###end p 29
###begin p 30
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Colorectal cancer in males; </bold>
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
Colorectal cancer in males; cumulative risks for MLH1, MSH2 and MSH6 mutation carriers.
###end p 30
###begin p 31
###xml 0 30 0 30 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Colorectal cancer in females; </bold>
###xml 51 55 51 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
Colorectal cancer in females; cumulative risks for MLH1, MSH2 and MSH6 mutation carriers.
###end p 31
###begin p 32
###xml 0 34 0 34 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Endometrial carcinoma in females; </bold>
###xml 55 59 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
Endometrial carcinoma in females; cumulative risks for MLH1, MSH2 and MSH6 mutation carriers.
###end p 32
###begin p 33
###xml 10 11 10 11 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 71 75 71 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 167 172 167 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 227 232 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 236 241 236 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 365 370 365 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 411 416 411 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 420 425 420 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 490 495 490 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 499 504 499 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 594 599 594 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 797 802 797 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 806 811 806 811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 872 877 872 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 974 978 974 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 988 993 988 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 1005 1010 1005 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 1036 1037 1036 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 1098 1103 1098 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 1145 1150 1145 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 1154 1159 1154 1159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
In Figure 2, the age related cumulative risk for CRC is shown for male MLH1, MSH2 and MSH6 mutation carriers. At age 70 years, the cumulative risk was the highest for MLH1 mutation carriers, 78%, while the cumulative risks for MSH2 and MSH6 mutation carriers were 57% and 54% respectively. There was no significant difference in age related cumulative risk between MSH6 mutation carriers (p = 0.05) compared to MLH1 and MSH2 mutation carriers. However, the highest increase in risk in male MLH1 and MSH2 mutation carriers was observed between the ages of 40 to 50 years, while the risk in male MSH6 mutation carriers mostly increased between the ages of 50 to 60 years. Although the age related risks were not significant different between the three different MMR genes, there was a trend in male MLH1 and MSH2 mutation carriers to develop CRC at an earlier age than male MSH6 mutation carriers. The cumulative risks for CRC in females were lower compared to males, 57% for MLH1, 52% for MSH2 and 30% for MSH6 mutation carriers (Figure 3), with a significantly lower age related cumulative risk in MSH6 mutation carriers (p = 0.001) compared to MLH1 and MSH2 mutation carriers.
###end p 33
###begin p 34
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 145 150 145 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 309 314 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 344 349 344 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 353 358 353 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
For endometrial carcinoma, the highest cumulative risk was observed in the MSH6 mutation carriers (61%), while the cumulative risks for MLH1 and MSH2 mutation carriers were 25% and 49% respectively. However, the log rank test showed no significant difference in age related cumulative risk (p = 0.58) between MSH6 mutation carriers compared to MLH1 and MSH2 mutation carriers.
###end p 34
###begin title 35
Median age of onset
###end title 35
###begin p 36
###xml 65 70 65 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 235 240 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 305 306 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 423 428 423 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 463 468 463 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 512 517 512 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 611 616 611 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 670 675 670 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 731 736 731 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 887 892 887 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 923 928 923 928 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 962 967 962 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 1011 1016 1011 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 1020 1024 1020 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 1036 1041 1036 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 1045 1049 1045 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6</italic>
###xml 1064 1069 1064 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 1073 1077 1073 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6</italic>
The median age of CRC onset in males was significantly higher in MSH6 mutation carriers (48 years; range 32-84 years) compared to MSH2 mutation carriers (43 years; range 20-51 years, p = 0.03), but not significantly higher compared to MLH1 mutation carriers (45 years; range 33-63 years, p = 0.07) (Table 2). For female mutation carriers, no significant differences in the median age of CRC onset were found when comparing MSH6 (53 years; range 34-61 years) with MLH1 (50 years; range 25-79 years, p = 0.88) and MSH2 (44 years; range 29-82 years, p = 0.28). The median age of EC onset was significant higher in MSH6 mutation carriers (56 years; 47-67 years) compared to MLH1 mutation carriers (51 years; 46-54 years, p = 0.02) and MSH2 mutation carriers (46 years; 36-55 years, p = 0.001). There were no significant differences in the age of onset of other LS-associated cancers between MLH1 (53 years; range 52-54 years), MSH2 (42 years; range 23-59 years) and MSH6 (50 years; range: 35-76) mutation carriers (MLH1 vs. MSH2, p = 0.41; MLH1 vs. MSH6, p = 0.76 and MSH2 vs. MSH6, p = 0.41).
###end p 36
###begin p 37
Median age and range at diagnosis of Lynch syndrome associated cancer
###end p 37
###begin title 38
Discussion
###end title 38
###begin p 39
###xml 250 258 <span type="species:ncbi:9606">patients</span>
In this study, we evaluated 246 individuals from 67 families with a proven mismatch repair gene mutation to determine the cumulative lifetime risk of developing cancer. Previous studies have shown different lifetime risks for developing CRC in Lynch patients.
###end p 39
###begin p 40
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 261 262 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 468 473 468 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 477 482 477 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 561 566 561 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 627 628 627 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 693 697 693 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 699 704 699 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 708 713 708 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 768 773 768 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 862 867 862 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 879 884 879 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 888 892 888 892 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 976 981 976 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 1059 1064 1059 1064 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 1068 1072 1068 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2</italic>
###xml 1088 1090 1088 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1121 1126 1121 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 1153 1158 1153 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 1162 1167 1162 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 1243 1248 1243 1248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 1258 1260 1258 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 1399 1401 1399 1401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
One of the first studies evaluating the lifetime risk reported a lifetime risk for CRC at age 75 years of 92% in males and 83% in females [10]. Most later studies reported somewhat similar risks for CRC ranging from 65-100% in males and 30-63% risk in females [7,11-13]. A more recently published study reported the lowest lifetime risk for CRC so far, 27% for males and 22% for females at age 70 years [15]. All these studies only evaluated the risks associated with MLH1 and MSH2 mutations. Thirty one percent of the families included in our study carried an MSH6 mutation. This frequency is higher than previously reported [4,21-23]. Studies evaluating the lifetime risks of cancer amongst MLH1, MSH2 and MSH6 families are sparse. A study evaluating the risk in 20 MSH6 families showed that colorectal cancer was less frequent and developed 10 years later in MSH6 compared to MLH1 and MSH2. In addition a significant higher lifetime risk of endometrial carcinoma of 71% in MSH6 mutation carriers with a later age of onset (54 years vs. 48 and 49 years for MLH1 and MSH2) was reported [17]. A German study comparing 27 MSH6 mutation families with 156 MLH1 and MSH2 mutation families confirmed the lower risk and later age of onset of CRC in MSH6 families [24]. These results were also confirmed by a recently published British study, but this study only included 11 proven MSH6 mutation carriers [18].
###end p 40
###begin p 41
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 99 104 99 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 198 203 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 345 350 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 354 359 354 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
Our study indicates that, however the cumulative risks of cancer at age 70 years in MLH1, MSH2 and MSH6 mutation carriers is similar, each mutated gene has a distinguishable cancer risk profile. In MSH6 mutation carriers the risk at age 70 years for developing CRC was the lowest in both male (54%) and female (30%) when compared to carriers of MLH1 and MSH2 mutations.
###end p 41
###begin p 42
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 199 204 199 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 208 213 208 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 379 384 379 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 388 393 388 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 486 491 486 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 737 739 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 796 801 796 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 971 976 971 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 995 997 995 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
Between male MSH6 and MSH2 mutation carriers also a significant difference in the age of CRC onset (48 vs. 43 years, p = 0.03) was found and there was a trend in higher age of CRC onset between male MSH6 and MLH1 mutation carriers. For female mutation carriers, no significant differences were found in the mean age of onset of CRC. This can be explained by the fact that female MLH1 and MSH2 mutation carriers still developed CRC at an older age. The lower risk of CRC onset in female MSH6 mutation carriers under the age of 50 years raises the question whether colonoscopic surveillance guidelines in these subjects can be changed. Current guidelines advise to start with biennial colonoscopy surveillance from the age of 20-25 years [25]. In our study population, the youngest affected female MSH6 mutation carrier with CRC was 34 years. Our data and the data from previous studies support that colonoscopic surveillance can be started at an age of 30 years in female MSH6 mutation carriers [17].
###end p 42
###begin p 43
###xml 106 111 106 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 133 138 133 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 142 147 142 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 265 269 265 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 271 276 271 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 280 285 280 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 382 387 382 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 417 422 417 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 676 678 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 705 710 705 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 772 777 772 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 781 786 781 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 938 940 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 941 943 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 956 961 956 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 1104 1106 1104 1106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1112 1117 1112 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 1121 1126 1121 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 1192 1197 1192 1197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 1336 1341 1336 1341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 1528 1533 1528 1533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1 </italic>
###xml 1536 1541 1536 1541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
However our numbers are too small to draw definite conclusions, CRC seems to be the predominant cancer in MLH1 mutation carriers. In MSH2 and MSH6 mutation carriers extracolonic cancers appear to contribute more to the similar cumulative lifetime risk of cancer in MLH1, MSH2 and MSH6 mutation carriers. A higher risk of extracolonic-LS-associated cancer was previously reported in MSH2 mutation carriers compared to MLH1 mutation carriers [13,19]. Unfortunately, the number of extracolonic-LS associated cancer (excluding endometrial carcinoma) in our study population was too low to calculate accurate risk estimates for these cancers. In concordance with other studies [17,26] our study indicates that MSH6 carriers have the highest endometrial cancer risk followed by MSH2 and MLH1 mutation carriers. Also, this risk increases sharply after the age of 50 years. In view of the disputable effect of endometrial carcinoma surveillance [27,28], in female MSH6 carriers aged 45 years or above prophylactic hysterectomy may be suggested in order to decrease the risk for developing endometrial carcinoma [29]. In MSH2 and MLH1 female mutation carriers this option may be more questionable. In MSH2 mutation carriers the risk of other extracolonic and extraendometrial cancers may reduce faith in and benefit of risk reducing surgery. In MLH1 mutation carriers the risk of endometrial cancer may not outweigh the disadvantages of surgery. In case of surgery for another cause, additional hysterectomy should be considered also in MLH1 en MSH2 mutation carriers.
###end p 43
###begin p 44
###xml 521 523 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 1123 1125 1123 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 1390 1394 1390 1394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 1396 1401 1396 1401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 1405 1410 1405 1410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 1053 1061 <span type="species:ncbi:9606">patients</span>
A strength of the present study was that the age related risks where calculated using proven mutation carriers. However, the age related risks might be somewhat lower since not all the unaffected individuals from proven mutation families opted for genetic testing and thus the total number of unaffected mutation carriers in the mutation families may be underestimated. In addition, individuals with a higher risk for mutation carriership, i.e. with an affected first degree relative, more often opt for genetic testing [30]. This may also have introduced some bias with respect to the age related risks. Also, we included the index cases in our study population. Index cases give rise to the suspicion of Lynch syndrome and they always have cancer. This may also have resulted in a slightly higher age related risk. On the other hand, the majority (77%) of not affected mutation carriers was under colonoscopy surveillance, which likely has influenced the age related risks for developing invasive CRC, since colonoscopy surveillance in Lynch syndrome patients is effective in reducing the incidence and mortality of CRC [31]. A limitation of our study was that our study population was not very large (n = 246), and the number of male carriers was 92. This could explain why we did not find a significant difference in both the mean age of CRC onset and the age related risk between male MLH1, MSH2 and MSH6 mutation carriers.
###end p 44
###begin p 45
###xml 119 123 119 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH2 </italic>
###xml 134 139 134 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 257 262 257 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 507 512 507 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 568 573 568 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
In conclusion, the present study indicates that, although the cumulative risks at age 70 years of LS related cancer in MLH1, MSH2 and MSH6 mutation carriers are similar, each mutated gene has a distinguishable cancer risk profile. It underlines that female MSH6 mutation carriers have a distinct clinical phenotype with a lower CRC risk and a higher risk for developing endometrial carcinoma. Starting with biennial colonoscopic surveillance at an age of 30 years instead of an age of 20-25 years in female MSH6 mutation carriers is more suitable. Moreover, in female MSH6 mutation carriers prophylactic hysterectomy may be considered from an age of 45 years.
###end p 45
###begin title 46
Conclusions
###end title 46
###begin p 47
###xml 105 110 105 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
###xml 287 292 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MSH6 </italic>
The present study indicates that each mutated MMR gene has a distinguishable cancer risk profile. Female MSH6 mutation carriers have a lower CRC risk and a higher risk for developing endometrial carcinoma. Starting with biennial colonoscopic surveillance at an age of 30 years in female MSH6 mutation carriers is more suitable and prophylactic hysterectomy may be considered from an age of 45 years.
###end p 47
###begin title 48
Abbreviations
###end title 48
###begin p 49
CRC: colorectal cancer; EC: endometrial cancer; LS: Lynch syndrome; MMR: mismatch repair; UV: unclassified variant.
###end p 49
###begin title 50
Competing interests
###end title 50
###begin p 51
The authors declare that they have no competing interests.
###end p 51
###begin title 52
Authors' contributions
###end title 52
###begin p 53
DR participated in the data collection, performed the statistical analyses and helped to draft the manuscript. AW conceived of the study and participated in the data collection. ML helped to draft the manuscript. DD participated in the data collection. CT participated in the data collection. ES participated in the design of the study and assisted in the statistical analysis. EK helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 53
###begin article-title 54
Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease
###end article-title 54
###begin article-title 55
Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer
###end article-title 55
###begin article-title 56
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer
###end article-title 56
###begin article-title 57
Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer
###end article-title 57
###begin article-title 58
Mutations of two PMS homologues in hereditary nonpolyposis colon cancer
###end article-title 58
###begin article-title 59
Characteristics of small bowel carcinoma in hereditary nonpolyposis colorectal carcinoma. International Collaborative Group on HNPCC
###end article-title 59
###begin article-title 60
Cancer risk in mutation carriers of DNA-mismatch-repair genes
###end article-title 60
###begin article-title 61
Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea
###end article-title 61
###begin article-title 62
The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome
###end article-title 62
###begin article-title 63
Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis
###end article-title 63
###begin article-title 64
Cancer risk associated with germline DNA mismatch repair gene mutations
###end article-title 64
###begin article-title 65
Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer
###end article-title 65
###begin article-title 66
MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families
###end article-title 66
###begin article-title 67
Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree
###end article-title 67
###begin article-title 68
Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment
###end article-title 68
###begin article-title 69
Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset
###end article-title 69
###begin article-title 70
Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance
###end article-title 70
###begin article-title 71
Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations
###end article-title 71
###begin article-title 72
Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population
###end article-title 72
###begin article-title 73
Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome)
###end article-title 73
###begin article-title 74
Mutations associated with HNPCC predisposition -- Update of ICG-HNPCC/INSiGHT mutation database
###end article-title 74
###begin article-title 75
MSH6 germline mutations are rare in colorectal cancer families
###end article-title 75
###begin article-title 76
Germ-line msh6 mutations in colorectal cancer families
###end article-title 76
###begin article-title 77
Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium
###end article-title 77
###begin article-title 78
Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer)
###end article-title 78
###begin article-title 79
Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations
###end article-title 79
###begin article-title 80
###xml 72 77 <span type="species:ncbi:9606">women</span>
The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma
###end article-title 80
###begin article-title 81
Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome
###end article-title 81
###begin article-title 82
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome
###end article-title 82
###begin article-title 83
The use of genetic testing in hereditary colorectal cancer syndromes: genetic testing in HNPCC, (A)FAP and MAP
###end article-title 83
###begin article-title 84
Decrease in mortality in Lynch syndrome families because of surveillance
###end article-title 84

